"This is not a statistically significant difference," Sanda said.
His research team suggested a better approach than broadly encouraging initial treatment, which significantly disrupts a patient's quality of life, would be treatment for high-risk prostate cancers and just initial monitoring for the low-risk tumors.
"This would avoid problems due to treatment of 'overdiagnosed' low-risk cancers, while preserving the life-saving benefits of treating aggressive cancers that have been detected through PSA testing," Sanda said.
Another study released Monday also suggested the largely successful PSA screening method has led to massive overdiagnoses for prostate cancer.
According to research published online in the Journal of the National Cancer Institute, since 1986 an additional 1.3 million men have been diagnosed with prostate cancer who would otherwise have never been diagnosed without the screening, and more than one million have been treated.
Researchers wrote that many of those overdiagnosed patients "are needlessly exposed to the hassle factors of obtaining treatment, the financial implications of the diagnosis, and the anxieties associated with becoming a cancer patient."
Source-AFP
SRM